Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Neoadjuvant chemotherapy followed by concurrent chemoradiation (CCRT) has been recommended in
the treatment of locoregionally-advanced nasopharyngeal carcinoma (NPC), with docetaxel,
cisplatin (DDP) and 5-fluorouracil (5-Fu) shown to be an effective regimen. Capecitabine is
the precursor drug of 5-fluorouracil, and has been used in replace of 5-fluorouracil in NPC
patients. Nab-paclitaxel (Nab-PTX) is a novel albumin-bound paclitaxel with a superior
therapeutic index to docetaxel. We sought to find out the efficacy of Nab-PTX in three-drug
triplet (Nab-PTX, DDP and capecitabine) and decide the best administration dose of Nab-PTX.